Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H1 2017

  • ID: 4315559
  • Report
  • 54 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Basilea Pharmaceutica Ltd
  • Celldex Therapeutics Inc
  • Celon Pharma SA
  • Ignyta Inc
  • Ono Pharmaceutical Co Ltd
  • Qurient Co Ltd
  • MORE
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H1 2017

Summary:

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Proto-oncogene tyrosine-protein kinase MER is an enzyme encoded by the MERTK gene. It regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells. It plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. It also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1.

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 12 and 2 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology and Ophthalmology which include indications Non-Small Cell Lung Cancer, Melanoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Breast Cancer, Glioblastoma Multiforme (GBM), Leukemias, Ovarian Cancer, Astrocytoma, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Esophageal Cancer, Gastric Cancer, Metastatic Colorectal Cancer, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Retinitis Pigmentosa (Retinitis) and Solid Tumor.

The latest report Tyrosine Protein Kinase Mer - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1)
  • The report reviews Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Basilea Pharmaceutica Ltd
  • Celldex Therapeutics Inc
  • Celon Pharma SA
  • Ignyta Inc
  • Ono Pharmaceutical Co Ltd
  • Qurient Co Ltd
  • MORE
  1. Introduction
  2. Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Overview
  3. Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Assessment
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Companies Involved in Therapeutics Development
  14. Basilea Pharmaceutica Ltd
  15. Celldex Therapeutics Inc
  16. Celon Pharma SA
  17. Dong-A Socio Holdings Co Ltd
  18. Ignyta Inc
  19. Ono Pharmaceutical Co Ltd
  20. Qurient Co Ltd
  21. Rigel Pharmaceuticals Inc
  22. SignalChem Lifesciences Corp
  23. Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Drug Profiles
  24. Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile
  25. Product Description
  26. Mechanism Of Action
  27. R&D Progress
  28. CCT-196969 - Drug Profile
  29. Product Description
  30. Mechanism Of Action
  31. R&D Progress
  32. CCT-241161 - Drug Profile
  33. Product Description
  34. Mechanism Of Action
  35. R&D Progress
  36. CT-413 - Drug Profile
  37. Product Description
  38. Mechanism Of Action
  39. R&D Progress
  40. DA-4501 - Drug Profile
  41. Product Description
  42. Mechanism Of Action
  43. R&D Progress
  44. Drugs to Inhibit MERTK for Oncology - Drug Profile
  45. Product Description
  46. Mechanism Of Action
  47. R&D Progress
  48. Gene Therapy to Activate MERTK for Retinitis Pigmentosa - Drug Profile
  49. Product Description
  50. Mechanism Of Action
  51. R&D Progress
  52. HOPE-777 - Drug Profile
  53. Product Description
  54. Mechanism Of Action
  55. R&D Progress
  56. Mer-590 - Drug Profile
  57. Product Description
  58. Mechanism Of Action
  59. R&D Progress
  60. MRX-2843 - Drug Profile
  61. Product Description
  62. Mechanism Of Action
  63. R&D Progress
  64. MRX-6313 - Drug Profile
  65. Product Description
  66. Mechanism Of Action
  67. R&D Progress
  68. ONO-7475 - Drug Profile
  69. Product Description
  70. Mechanism Of Action
  71. R&D Progress
  72. Q-701 - Drug Profile
  73. Product Description
  74. Mechanism Of Action
  75. R&D Progress
  76. RXDX-106 - Drug Profile
  77. Product Description
  78. Mechanism Of Action
  79. R&D Progress
  80. Small Molecules to Inhibit Mer Tyrosine Kinase for Oncology - Drug Profile
  81. Product Description
  82. Mechanism Of Action
  83. R&D Progress
  84. Small Molecules to Inhibit MerTK for Oncology - Drug Profile
  85. Product Description
  86. Mechanism Of Action
  87. R&D Progress
  88. UNC-569 - Drug Profile
  89. Product Description
  90. Mechanism Of Action
  91. R&D Progress
  92. Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Dormant Products
  93. Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Product Development Milestones
  94. Featured News & Press Releases
  95. Apr 04, 2017: Ignyta Announces New Data Highlighting Broad Potential of RXDX-106 at the 2017 AACR Annual Meeting
  96. Mar 28, 2017: Ignyta Announces Multiple Presentations at the 2017 AACR Annual Meeting
  97. Nov 29, 2016: Ignyta to Debut Preclinical Data on RXDX-106 at the 2016 EORTC-NCI-AACR Annual Meeting
  98. Mar 21, 2016: New Kinase Inhibitor Effective against Drug-Resistant Leukemia, Preclinical Study Finds
  99. Mar 11, 2013: Therapies for ALL and AML targeting MER receptor hold promise of more effect with less side-effect
  100. Jun 08, 2010: Graham’s Work In Pediatric Leukemia Genes Earns Him $1.3 Million In Grants To Test Targeted Drugs
  101. Jun 08, 2010: Graham’s Work In Pediatric Leukemia Genes Earns Him $1.3 Million In Grants To Test Targeted Drugs
  102. Appendix
  103. Methodology
  104. Coverage
  105. Secondary Research
  106. Primary Research
  107. Expert Panel Validation
  108. Contact Us
  109. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indication, H1
  4. Number of Products under Development by Companies, H1
  5. Products under Development by Companies, H1
  6. Products under Development by Companies, H1 2017 (Contd..1), H1
  7. Number of Products under Investigation by Universities/Institutes, H1
  8. Products under Investigation by Universities/Institutes, H1
  9. Number of Products by Stage and Mechanism of Actions, H1
  10. Number of Products by Stage and Route of Administration, H1
  11. Number of Products by Stage and Molecule Type, H1
  12. Pipeline by Basilea Pharmaceutica Ltd, H1
  13. Pipeline by Celldex Therapeutics Inc, H1
  14. Pipeline by Celon Pharma SA, H1
  15. Pipeline by Dong-A Socio Holdings Co Ltd, H1
  16. Pipeline by Ignyta Inc, H1
  17. Pipeline by Ono Pharmaceutical Co Ltd, H1
  18. Pipeline by Qurient Co Ltd, H1
  19. Pipeline by Rigel Pharmaceuticals Inc, H1
  20. Pipeline by SignalChem Lifesciences Corp, H1
  21. Dormant Projects, H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Top 10 Indications, H1
  4. Number of Products by Mechanism of Actions, H1
  5. Number of Products by Stage and Mechanism of Actions, H1
  6. Number of Products by Routes of Administration, H1
  7. Number of Products by Stage and Routes of Administration, H1
  8. Number of Products by Molecule Types, H1
  9. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Basilea Pharmaceutica Ltd
  • Celldex Therapeutics Inc
  • Celon Pharma SA
  • Dong-A Socio Holdings Co Ltd
  • Ignyta Inc
  • Ono Pharmaceutical Co Ltd
  • Qurient Co Ltd
  • Rigel Pharmaceuticals Inc
  • SignalChem Lifesciences Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll